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Alcohol consumption is the major cause of chronic
pancreatitis. Autoimmunity is a rare but important
cause of chronic pancreatitis. In 1995, Yoshida et al1
first proposed the term autoimmune pancreatitis
(AIP). They reviewed 11 patients with AIP in the lit-
erature and found that diffuse pancreas enlargement
and diffuse irregular narrowing of the main pancreatic
duct on endoscopic retrograde pancreatogram were
major characteristic features. In addition, increased
serum IgG is a serologic characteristic. The clinical,
radiologic, histologic and serologic features and favor-
able response to steroids comprise the diagnostic cri-
teria of AIP.2 AIP is a clinically interesting entity and
has become an important topic at worldwide digestive
disease conferences in recent years.
Most cases of AIP have been reported from Japan.
However, reports of AIP from Western countries
have been increasing in recent years.3–6 Most reports
have shown that the disease predominantly affects
middle-aged to elderly men.6,7 The prevalence of AIP
is not clear. According to a nationwide survey in
Japan, the prevalence of patients with AIP was esti-
mated to be 0.82 per 100,000.7 The male to female
ratio was 2.85:1, and the age of disease onset in 95%
of the patients was over 45 years. The percentage of
AIP in patients with chronic pancreatitis is reported
to be 4.6–6%.3 In this issue of the Journal of the
Chinese Medical Association, Lin et al8 report 5 cases
of AIP in Taiwan. They retrospectively reviewed the
patients’ clinical presentations and treatment responses.
There were 2 male and 3 female patients, with a mean
age of 61 years.
Patients with chronic pancreatitis, especially AIP,
and pancreatic cancer share many clinical features, such
as obstructive jaundice, pancreatic mass, and stenosis
of both pancreatic and bile ducts. Occasionally, AIP is
diagnosed by histopathology after Whipple’s opera-
tion has been undertaken as pancreatic malignancy is
presumed with initial imaging studies. Patients with
AIP rarely complain of severe abdominal pain typical
of pancreatitis. The major presenting symptoms of
AIP are obstructive jaundice, mild abdominal pain and
weight loss. In Lin et al’s report,8 4 of the 5 patients
with AIP had these 3 major symptoms. In 2 patients,
AIP was diagnosed after operation for presumed pan-
creatic tumor. Three of the 5 patients had diabetes
mellitus. Diabetes mellitus is often noted in patients
with AIP, with an incidence ranging from 42% to
76%.3 Most of these cases are diagnosed as new-onset
diabetes.
Although 4 diagnostic criteria from Japan, Korea,
USA and Italy for AIP have been proposed, a consensus
for establishing the diagnosis has not been achieved.2
In the criteria from Japan and Korea, pancreatic
imaging of diffuse pancreas enlargement together
with main pancreatic duct narrowing is a mandatory
criterion. At least 1 of the supportive criteria including
serology (autoantibodies, IgG and IgG4), histopathol-
ogy (fibrosis and lymphoplasmacytic infiltration) and
response to steroid (not included in the criteria by 
the Japan Pancreas Society) is also required for the
diagnosis of AIP. Comparison of imaging findings
among AIP, alcoholic chronic pancreatitis and pan-
creatic cancer is shown in Table 1. Rare pancreatic
calcification or cyst is a characteristic of AIP. If endo-
scopic retrograde cholangiopancreatography or mag-
netic resonance cholangiopancreatography is not done,
the diagnosis of AIP would be somewhat difficult.
Hypergammaglobulinemia in patients with AIP
ranges from 37% to 76%.3 Increased serum IgG4 is a
highly sensitive and specific marker for AIP.4–6,9 The
sensitivity of IgG4 for AIP is shown to be higher than
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that of IgG.3 Can IgG4 distinguish AIP from pancreatic
cancer? Ghazale et al5 measured serum IgG4 levels
(normal, 8–140 mg/dL) in 45 patients with AIP and
135 patients with pancreatic cancer. They found that
the sensitivity and specificity of elevated serum IgG4
(>140 mg/dL) for the diagnosis of AIP were 76%
and 93%, respectively. Serum IgG4 levels were ele-
vated in 10% of pancreatic cancer patients. Conversely,
CA19-9 levels >100 U/mL were found in 9% of AIP
patients, compared with 71% of pancreatic cancer
patients.5 In Lin et al’s report,8 serum IgG levels were
measured in 4 patients and found to be increased 
in all of them. Antinuclear antibody was positive in 
3 patients. Unfortunately, IgG4 was not measured 
in their study.
Extrapancreatic involvement is a particular feature
of AIP. Intrahepatic and exprahepatic duct (including
hilar area) stricturing is increasingly recognized as a
part of the spectrum of AIP.6 What is the difference in
the imaging of bile duct abnormalities between AIP
with sclerosing cholangitis and primary sclerosing
cholangitis? Nakazawa et al10 reported that the abnor-
mal intrahepatic ducts in AIP are characterized by
segmental stricture or long stricture with prestenotic
dilatation, while band-like stricture, beaded or pruned-
tree appearance, and diverticulum-like formation are
more commonly seen in primary sclerosing cholangitis.
Other autoimmune manifestations accompanying AIP
include Sjögren’s syndrome, psoriasis, inflammatory
bowel disease, rheumatoid arthritis, renal mass, tubu-
lointerstitial nephritis, sclerosing cholecystitis, scleros-
ing cholangitis, stenosis of intrahepatic bile ducts,
sclerosing sialoadenitis, swelling of cervical lymph
nodes, and retroperitoneal fibrosis. Histopathologic
findings of these extrapancreatic lesions are lympho-
plasmacytic infiltration with fibrosis and obliterated
phlebitis, similar to those of the pancreas. Association
of AIP with other autoimmune diseases was reported
in 12–50% of patients.3 In the report of Lin et al,8 only
1 of the 5 patients with AIP had associated autoimmune
disease (Sjögren’s syndrome). Because of the demon-
stration of extrapancreatic involvement in many patients
with AIP, autoimmune pancreatitis was supposed to
be too restrictive a term. IgG4-related systemic/sclerosing
disease has been proposed.11
A good response to steroids is a characteristic of AIP.
Church et al6 followed-up 11 patients and showed
rapid symptomatic response to steroids within the first
4 weeks, and liver biochemistry improvement within
2 months and imaging resolution in all patients. Biliary
stents were placed in 7 patients, and all stents were
removed without recurrence of jaundice over a median
follow-up of 8 months.6 AIP was reported to progress
in the absence of steroids. Optimum treatment 
regimens have not been determined for patients with
AIP. The recommended dosage of oral prednisolone
is 30–40 mg daily, then gradually reduced over 
2–3 months to a maintenance dose of 2.5–10 mg daily
according to response.6 Recurrence of AIP after steroid
therapy is not well known. Disease relapse occurred in
55% of patients with AIP on low-dose steroids or fol-
lowing cessation.6 Most of these patients responded
to increased steroids and the addition of azathioprine.
In the report of Lin et al,8 steroid therapy was given to
3 patients who were responsive, but 2 patients experi-
enced recurrence.
Is a persistently elevated or increasing serum IgG4
level on steroids a predictor of disease relapse? Does
AIP predispose to pancreatic or biliary malignancy as
in the case of chronic pancreatitis or primary scleros-
ing cholangitis? Could steroid therapy alter the course
of the disease? Long-term follow-up studies are
required to answer these questions.
In conclusion, knowledge of AIP and IgG4-related
sclerosing disease has been emerging and attracting
more attention in recent years. Although it is a relatively
rare disease, early and accurate diagnosis may avoid
unnecessary operation and lead to good treatment
response. What constitutes optimal long-term man-
agement needs further investigation.
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Table 1. Comparison of imaging findings among autoimmune pancreatitis (AIP), alcoholic chronic pancreatitis (ACP) and 
pancreatic cancer
AIP ACP Pancreatic cancer
Complete obstruction of MPD Uncommon Uncommon Common
Ductal stricture Multiple Multiple Single
Upstream MPD dilatation Mild Marked Marked
Double duct sign Common Occasional Common
Pancreatic parenchyma Diffuse swelling Atrophy Focal mass
Calcification of pancreas Uncommon Common Occasional
Pancreatic pseudocyst Uncommon Common Uncommon
MPD = main pancreatic duct.
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